The in vitro diagnostic company said it would use the financing to commercialize its antibiotic susceptibility platform called Reveal.
The firm said it anticipates using the loan proceeds to fund its pursuit of corporate priorities, including broadening its product portfolio and geographic reach.
The company, founded earlier this year, is developing a technology for the detection of low-frequency genetic mutations for diagnostic applications.
The company is developing a test to predict the risk of a melanoma patient's cancer metastasizing in lymph nodes without the need for biopsy.
The firm did not disclose the size of the funding, which is helping it build on its Centrellis Health Intelligence Platform and move to whole-exome sequencing.
The Oakland, California-based company will use the funding to speed the manufacturing and commercialization of its dual alcohol and marijuana breathalyzer.
The firm said that it is working with partners to provide collection devices that can be used at home, making it easier for people to gain access to tests.
The firm said that it is developing an over-the-counter diagnostic technology to detect mosquito-borne illnesses in minutes instead of days.
The Tokyo-based firm said it will use the funding to support prototyping and commercialization of its mass spectrometry and optical spectroscopy instruments.
The firm said it will use the funding to invest in research and development that will improve upon its deep shotgun metagenomic sequencing technology.